Search Results - "Bandini, Lorenza"
-
1
ETV6::ABL1 -Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment
Published in International journal of molecular sciences (01-01-2024)“…rearranged neoplasms are rare hematological diseases. To date, about 80 cases have been reported, including myeloid and lymphoid leukemias. The gene codes for…”
Get full text
Journal Article -
2
Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1 + TIM3 + exhausted CD8 + T cells
Published in Frontiers in immunology (15-05-2024)“…Acute myeloid leukemia (AML) is an aggressive heterogeneous disease characterized by several alterations of the immune system prompting disease progression and…”
Get full text
Journal Article -
3
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets
Published in International journal of molecular sciences (17-09-2024)“…Acute myeloid leukemia (AML) is an aggressive hematologic neoplasia with a complex polyclonal architecture. Among driver lesions, those involving the gene…”
Get full text
Journal Article -
4
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
Published in Frontiers in oncology (30-09-2021)“…FMS-like tyrosine kinase 3 (FLT3) is among the most common driver genes recurrently mutated in acute myeloid leukemia (AML), accounting for approximately 30%…”
Get full text
Journal Article -
5
PB1865: NPM1‐MUT MONITORING DURING GILTERITINIB TREATMENT IDENTIFIES DIFFERENT DYNAMICAL PATTERNS IN RESPONSIVE PATIENTS
Published in HemaSphere (08-08-2023)Get full text
Journal Article -
6
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study
Published in Cancer medicine (Malden, MA) (01-05-2023)“…Background In older patients with acute myeloid leukemia (AML), the definition of fitness, prognosis, and risk of death represents an open question. Methods In…”
Get full text
Journal Article -
7
Iron-Related Laboratory Profile May Predict Response and MRD Negativity Rate in Acute Myeloid Leukemia Patients
Published in Blood (02-11-2023)“…Introduction: iron metabolism is deeply related to the pathogenesis and prognosis of acute myeloid leukemia (AML) and remains largely unexplored in the era of…”
Get full text
Journal Article -
8
A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure
Published in Blood (15-11-2022)Get full text
Journal Article -
9
IETV6::ABL1/I-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment
Published in International journal of molecular sciences (01-12-2023)“…ETV6::ABL1 rearranged neoplasms are rare hematological diseases. To date, about 80 cases have been reported, including myeloid and lymphoid leukemias. The ETV6…”
Get full text
Journal Article -
10
T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia
Published in Blood (02-11-2023)“…S.R. & A.C. equally contributed Background: Despite significative improvements in the management of FLT3-mutated AML and its prognosis since FLT3 inhibitors (…”
Get full text
Journal Article -
11
An Outpatient Management for First Cycle of Venetoclax and Hypomethylating Agents Results in Reduced Infection Rate and Hospitalizations in Acute Myeloid Leukemia Patients
Published in Blood (23-11-2021)“…Introduction In the setting of clinical trials Venetoclax (VEN) combined with hypomethylating agents (HMAs) has shown fair activity in Relapsed/Refractory…”
Get full text
Journal Article -
12
IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease
Published in Blood (23-11-2021)“…Rationale: Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutations may be the nearest signal to in vivo leukemogenesis that we are able to see in overt acute…”
Get full text
Journal Article -
13
Release of IFN-γ by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells
Published in Clinical cancer research (15-07-2022)“…The stromal and immune bone marrow (BM) landscape is emerging as a crucial determinant for acute myeloid leukemia (AML). Regulatory T cells (Tregs) are…”
Get full text
Journal Article -
14
Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents
Published in Blood (23-11-2021)“…BACKGROUND: Many efforts have been made in the attempt to address the conundrum question of fitness definition ad prognosis prediction in elderly acute myeloid…”
Get full text
Journal Article -
15
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents
Published in European journal of haematology (01-06-2022)“…Venetoclax (VEN) and hypomethylating agent (HMAs) regimens are emerging as the standard of care for unfit for chemotherapy acute myeloid leukemia (AML)…”
Get full text
Journal Article -
16
AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA)
Published in Blood (13-11-2019)“…Background Although much efforts have been made to precisely define fitness of AML patients, in patients who are not candidate to chemotherapy, there is no…”
Get full text
Journal Article -
17
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia
Published in Journal of oncology (2019)“…Somatic mutations of DNMT3A occur in about 20% of acute myeloid leukemia (AML) patients. They mostly consist in heterozygous missense mutations targeting a…”
Get full text
Journal Article -
18
ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment
Published in International journal of molecular sciences (21-12-2023)“…ETV6::ABL1 rearranged neoplasms are rare hematological diseases. To date, about 80 cases have been reported, including myeloid and lymphoid leukemias. The ETV6…”
Get full text
Report -
19
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
Published in Frontiers in oncology (01-01-2021)Get full text
Report